Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 32.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 476,023 shares of the biopharmaceutical company's stock after purchasing an additional 115,832 shares during the period. Janus Henderson Group PLC owned approximately 0.40% of Catalyst Pharmaceuticals worth $9,935,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at $27,000. Farther Finance Advisors LLC boosted its position in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth about $65,000. KBC Group NV increased its position in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 1,542 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $104,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock traded down $0.37 on Thursday, hitting $23.95. 139,365 shares of the stock traded hands, compared to its average volume of 1,102,584. The company's fifty day moving average is $23.44 and its 200 day moving average is $22.52. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.75 and a 1-year high of $26.16. The company has a market capitalization of $2.92 billion, a PE ratio of 20.30, a PEG ratio of 3.31 and a beta of 0.70.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CPRX. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Wall Street Zen upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Stephens restated an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Robert W. Baird raised their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals has an average rating of "Buy" and a consensus target price of $32.29.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gary Ingenito sold 44,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total value of $1,039,720.00. Following the completion of the transaction, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,627,468.99. The trade was a 38.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 351,879 shares of company stock worth $8,214,815 over the last 90 days. Insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.